CrystalO Biopharma announced that it has received $15.700000 million in funding from a group of investors and another investor.

CrystalO Biopharma announced that it has received $15,700,000 in funding led by Zhuhai Longmen Capital Management Co. on January 7, 2022. The transaction included participation from Goldport Capital, Technology Financial Group, Shenzhen Tiantu Investment Management Co., Ltd., Shenzhen Qianhai Hongzhao Fund Management Co., Ltd., HitGen Inc., Caixiang Technology, and Space Holding Group.